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ABSTRACT 
Five Ru(II)(6-toluene) complexes formed with 2-picolinic acid and its various derivatives have 
been synthesized and characterized. X-ray structures of four complexes are also reported. 
Complex formation processes of [Ru(II)(6-toluene)(H2O)3]2+ organometallic cation with the 
metal-free ligands were studied in aqueous solution in the presence of chloride ions by the 
combined use of 1H NMR spectroscopy, UV-visible spectrophotometry and pH-potentiometry. 
Solution stability, chloride ion affinity and lipophilicity of the complexes were characterized 
together with the in vitro cytotoxic and antiproliferative activity in cancer cell lines being 
sensitive and resistant to classic chemotherapy and in normal cells as well. Formation of mono 
complexes such as [Ru(6-toluene)(L)(Z)] (L: completely deprotonated ligand; Z = H2O/Cl‒) 
with high stability and [Ru(6-toluene)(L)(OH)] was found in solution. The pKa values (8.3-
8.7) reflect the formation of low amount of mixed hydroxido species at pH 7.4 at 0.2 M KCl 
ionic strength. The complexes are fairly hydrophilic and show moderate chloride ion affinity 
and fast chloride-water exchange processes. The studied complexes exhibit no cytotoxic 
activity in human cancer cells (IC50 > 100 M), only complexes formed with 2-picolinic acid 
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(1) and its 3-methyl derivative (2) represented a moderate antiproliferative effect (IC50 = 84.8 
(1), 79.2 μM (2)) on a multidrug resistant (MDR) colon adenocarcinoma cell line revealing 
considerable MDR selectivity. Complexes 1 and 2 are bound to human serum albumin 
covalently and relatively slowly with moderate strength at multiple binding sites without ligand 
cleavage.   
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1. Introduction 
  
 Ruthenium complexes have emerged as attractive alternatives to platinum based 
compounds such as cisplatin, carboplatin and oxaliplatin which are undoubtedly successful 
anticancer drugs but have several drawbacks such as serious side-effects and lack of activity 
(drug resistance) against certain types of cancer. Ruthenium compounds have different physico-
chemical and pharmacokinetic properties compared to the platinum drugs, and they have 
different mechanism of action as well, this is the reason why they are the subject of extensive 
drug discovery efforts [1-3]. Imidazolium trans-
[tetrachlorido(DMSO)(imidazole)ruthenate(III)] (NAMI-A) was the first Ru(III) complex 
reached clinical trials [4], while sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] 
(NKP-1339, IT-139) is one of the most promising investigational non-Pt drugs in current 
clinical development. NKP-1339 is active against solid malignancies such as non-small cell 
lung cancer, colorectal carcinoma and the treatment is accompanied by minor side effects [5,6]. 
While cisplatin induces DNA damage via adduct formation [7], endoplasmic reticulum stress 
and reactive oxygen species-related effects were found to be involved in the mechanism of 
action of NKP-1339 [5,8]. Ru(III) complexes are considered as prodrugs that are activated by 
reduction and it provides the impetus for the development of various Ru(II) anticancer 
compounds [5]. It is noteworthy that a novel Ru(II) compound [Ru(4,4’-dimethyl-2,2’-
bipyridine)2-(2-(2’,2’’:5’’,2’’’-terthiophene)-imidazo[4,5-f][1,10]phenanthroline)]Cl2 (TLD-
1433) has entered a human clinical trial recently as nontoxic photosensitizing agent [9]. Ru(II) 
is often stabilized in the +2 oxidation state by the coordination of η6-arene type ligands and 
there are two main prototypes of Ru(II)-arene complexes [3]: i) RAPTA compounds contain 
1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane (PTA) such as [Ru(6-p-cymene)(PTA)Cl2] 
(RAPTA-C) possessing significant antimetastatic property and is ready for translation into 
clinical evaluation [10,11]; ii) RAED complexes bear the bidentate 1,2-ethylenediamine (en) 
ligand such as [Ru(6-biphenyl)(en)Cl]PF6 (RM175) that has a similar cytotoxic activity to 
cisplatin [12,13]. In most of the half-sandwich organoruthenium(II) compounds a bidentate 
ligand with an (O,O), (O,S), (O,N), (N,N) or (N,S) binding mode is coordinated and a chloride 
ion acts as the leaving group [3,14-16]. Aquation (replacement of the chlorido ligand by a water 
molecule) facilitates the reaction with biological macromolecules such as proteins or DNA, 
therefore the strength of the Ru-Cl bond and the rate of its cleavage have a strong impact on the 
bioactivity of the Ru(II)-arene complexes [17]. Notably, the chemical and pharmacological 
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properties of the Ru(II)-arene half-sandwich compounds can be fine-tuned by variation of the 
coordinating ligand, the arene ring and the leaving group [1,3,10]. Although a large number of 
Ru(II)-arene compounds has been developed and extensively investigated, information about 
their solution speciation and stability constants is still limited in the literature. Most of the 
solution equilibrium studies are focused on [Ru(6-p-cymene)(X,Y)Cl] type complexes [18-
24]. For the better understanding of the pharmacokinetic properties and mechanisms of action 
of these metal complexes, the knowledge of the aqueous chemistry and the most plausible 
chemical forms in water, especially at physiological pH, is a mandatory prerequisite.  
 In our previous works we have studied the biological activity of Ru(II)(6-p-cymene) 
complexes of various pyridine derivatives [25-28] and moderate-to-low cytotoxicity was found 
in six tumor cell lines; although the complex of 2-picolinic acid (picH) represents an enhanced 
antiproliferative activity (e.g. IC50 = 82 M in HeLa cells, 36 M in FemX cells [27]) and 
antimetastatic effect based on wound migration assay [25]. The solution speciation of 
Ru(II)(6-p-cymene) picolinate complexes was also studied by some of us revealing the 
formation of mono-ligand complexes with high stabilities [23]. Notably, the Os(II) congener of 
the picolinate complex showed very high in vitro cytotoxic activity [29]. 
 As the physico-chemical and biological properties can be modified by the exchange of 
the arene ring, in this work we have prepared and structurally characterized Ru(II)(6-toluene) 
complexes formed with picH and its 3-methyl (3-Me-picH), 5-bromo (5-Br-picH), 2,4-
dicarboxylic (2,4-dipicH2) and 2,5-dicarboxylic (2,5-dipicH2) derivatives (Chart 1). In addition 
to the determination of the solid phase structures of the four complexes by X-ray 
crystallography, solution speciation of these Ru(II)(6-toluene) complexes in water was 
revealed by pH-potentiometry, 1H NMR spectroscopy and UV-visible (UV-vis) 
spectrophotometry involving studies on their stability and chloride ion affinity. The 
antiproliferative and cytotoxic effectiveness of these complexes in multidrug resistant/non-
resistant human cancer lines wasere also tested. Interactions between human serum albumin 
and the complexes showing antiproliferative effect were monitored using fluorometry and 
ultrafiltration. 
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Chart 1. Chemical structures of the ligands in their completely deprotonated forms (a) and the general 
formula of the prepared [Ru(6-toluene)(L)(Cl)] complexes. 
 
2. Experimental 
 
2.1. Chemicals 
All solvents were of analytical grade and used without further purification. Pyridine-2-
carboxylic acid (2-picolinic acid, picH), 3-methylpyridine-2-carboxylic acid (3-Me-picH), 5-
bromo-2-pyridinecarboxylic acid (5-Br-picH), 2,4-pyridinedicarboxylic acid monohydrate 
(2,4-dipicH2·H2O), 2,5-pyridinedicarboxylic acid (2,5-dipicH2), RuCl3·3H2O, KCl, HCl, KOH, 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 1-methylimidazole (N-MeIm), human 
serum albumin (HSA, as lyophilized powder with fatty acids, A1653), KH2PO4, 
NaH2PO4·2H2O, Na2HPO4·2H2O were purchased from Sigma-Aldrich in puriss quality. Doubly 
distilled Milli-Q water was used for preparation of samples. The purity of the ligands and the 
exact concentration of their stock solutions were determined by pH-potentiometric titrations 
and by the computer program HYPERQUAD [30]. [Ru(η6-toluene)Cl2]2 was prepared 
according to a well known procedure [31]. A stock solution of [Ru(η6-toluene)(Z)3], where Z 
is H2O or Cl
‒, was obtained by dissolving [Ru(η6-toluene)Cl2]2 in water and the exact 
concentration of this stock was determined with pH-potentiometric titrations. The modified 
phosphate-buffered saline (PBS’) contains 12 mM Na2HPO4, 3 mM KH2PO4, 1.5 mM KCl and 
100.5 mM NaCl; and the concentration of the K+, Na+ and Cl‒ ions corresponds to that of the 
human blood serum. HSA solution was freshly prepared before the experiments and its 
concentration was estimated from its UV absorption: 280 nm(HSA) = 36850 M−1cm−1 [32]. Stock 
solution of N-MeIm was prepared on a weight-in-volume basis in PBS’ solution. 
 
2.2. Synthesis of the complex [(η6-toluene)RuCl(μ-Cl)]2 with different picolinic acids 
 
2.2.1. Synthesis of the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 
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[Ru(η6-toluene)Cl(μ-Cl)]2 was prepared according the literature procedure used for the 
analogous [Ru(η6-benzene)Cl(μ-Cl)]2 [31] by adding 5 mL of 1-methyl-1,4-cyclohexadiene to 
a solution of 0.5 g RuCl3·3H2O (1.9 mmol) in 40 mL of absolute ethanol. This mixture was 
refluxed for 8 h. The reddish brown precipitate formed during the synthesis was filtered off, 
washed with diethyl ether and left to dry in exsiccator. Yield: 85%, 0.450 g; 1H NMR 
(500.26 MHz, DMSO-d6, d, ppm): 2.12 (3H, s, CH3), 5.68 (3H, m, C2, C4, C6 arene), 5.97 (2H, 
m, C3, C5 arene); 13C NMR (125.79 MHz MHz, DMSO-d6) 18.73 (CH3), 82.22 (C4 arene), 
84.83 (C5, C3 arene), 89.28 (C6, C2 arene), 105.82 (C1 arene). 
 
2.2.2. Synthesis of chlorido[(pyridine-κN-2-carboxylato-κO)(η6-toluene)ruthenium(II)] (1): 
To a warm solution of [Ru(η6-toluene)Cl2]2 (0.030 g, 0.057 mmol) in 25 mL of 2-propanol, was 
added a solution of picH (0.015 g, 0.13 mmol) in 2 mL of 2-propanol. The reaction mixture was 
stirred at room temperature for 7 days and the yellow-range precipitate was formed. Solution 
was filtered off and product was dried in exsiccator. Yield: 58%, 0.023 g; 1H NMR (500.26 
MHz, DMSO-d6, , ppm): 2.15 (3H, s, CH3), 5.60 (2H, m, C2, C6 arene), 5.70 (1H, m, C4 
arene), 5.99 (2H, m, C3, C5 arene), 7.72 (2H, m, C3, C4 ligand), 8.06 (1H, t, C5 ligand), 9.29 
(1H, d, C6 ligand); 13C NMR (125.79 MHz, DMSO-d6) 18.57 (CH3), 77.07 (C4 arene), 78.44 
(C5 arene), 79.71 (C3 arene), 86.15 (C6 arene), 88.06 (C2 arene), 101.01 (C1 arene), 125.31 
(C3 ligand), 128.09 (C5 ligand), 139.64 (C4 ligand), 150.89 (C2 ligand), 153.88 (C6 ligand). 
ESI/MS (m/z): [M‒Cl]+ = 315 and [M‒Cl‒COO+H+]+ = 272. 
 
2.2.3. Synthesis of complexes of chlorido[(3-methylpyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (2), chlorido[(5-bromopyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (3), chlorido[(4-carboxylate-pyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (4), chlorido[(5-carboxylate-pyridine-κN-2-carboxylato-κO)(η6-
toluene)ruthenium(II)] (5): 
Methanolic solution of the ligand (3-Me-picH (10.4 mg, 0.076 mmol) or 5-Br-picH (15.4 mg, 
0.076 mmol) or 2,4-dipicH2·H2O (14.1 mg, 0.076 mmol) or 2,5-dipicH2 (12.7 mg, 0.076 mmol)) 
was slowly added in the methanolic (5 mL) solution of [Ru(η6-p-toluene)Cl2]2 (20.0 mg, 0.038 
mmol) and reaction mixture was stirred for 3 h, at  40°C. Then, reaction volume was reduced 
to half and desired orange complex was precipitated. Solution was filtered off and product was 
dried in exsiccator. 
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2: Yield: 57%, 0.016 g; 1H NMR (500.26 MHz, DMSO-d6, , ppm): 2.16 (3H, s, arene CH3), 
2.54 (3H, s, ligand CH3), 5.57 (1H, d,C2, arene), 5.60 (1H, d, C6, arene), 5.68 (1H, t, C4 arene), 
5.97 (2H, dd, C3, C5 arene), 7.59 (1H, dd, C5 ligand), 7.89 (1H, d, C4 ligand), 9.22 (1H, d, C6 
ligand); 13C NMR (125.79 MHz, DMSO-d6) 18.37 (CH3, ligand), 18.65 (CH3, arene), 77.11 
(C4 arene), 78.88 (C5 arene), 79.21 (C3 arene), 86.62 (C6 arene), 88.43 (C2 arene), 101.18 (C1 
arene), 126.88 (C5 ligand), 137.92 (C4 ligand), 142.70 (C6 ligand), 147.29 (C3 ligand), 152.48 
(C2 ligand), 170.89 (COO-Ru). ESI/MS (m/z): [M‒Cl]+ = 330 and [M‒Cl‒COO+H+]+ = 287. 
3: Yield: 52%, 0.017 g; 1H NMR (500.26 MHz, DMSO-d6, , ppm): 2.17 (3H, s, CH3), 5.63 
and 5.67 (2H,dd ,C2, C6 arene), 5.77 (1H, t,C4 arene), 6.06 (2H, m, C3, C5 arene), 7.68 (1H, 
d, C3 ligand), 8.34 (1H, d, C4 ligand), 9.52 (1H, s, C6 ligand); 13C NMR (125.79 MHz, DMSO-
d6) 18.41 (CH3), 76.98 (C4 arene), 78.54 (C5 arene), 79.21 (C3 arene), 86.58 (C6 arene), 88.16 
(C2 arene), 101.60 (C1 arene), 122.95 (C5 ligand), 126.30 (C3 ligand), 142.28 (C4 ligand), 
149.76 (C2 ligand), 154.04 (C6 ligand), 169.69 (COO-Ru). ESI/MS (m/z): [M‒Cl]+ = 395 and 
[M‒Cl‒COO+H+]+ = 352. 
4: Yield: 56%, 0.017 g; 1H NMR (500.26 MHz, DMSO-d6, , ppm): 2.18 (3H, s, CH3), 5.66 
(2H,dd ,C2, C6 arene),5.75 (1H, t,C4 arene), 6.06 (2H, m, C3, C5 arene), 8.06 (2H, m, C3, C5 
ligand), 9.51 (1H, d, C6 ligand), 14.22 (1H, s, free COOH ligand); 13C NMR (125.79 MHz, 
DMSO-d6) 18.41 (CH3), 77.27 (C4 arene), 78.94 (C5 arene), 79.68 (C3 arene), 86.61 (C6 
arene), 88.17 (C2 arene), 101.54 (C1 arene), 123.82 (C3 ligand), 126.63 (C5 ligand), 140.93 
(C4 ligand), 151.88 (C6 ligand), 155.17 (C2 ligand), 164.66 (COO-Ru), 169.73 (COOH). 
ESI/MS (m/z): [M‒Cl]+ = 360 and [M‒Cl‒COO+H+]+ = 317. 
5: Yield: 50%, 0.015 g; 1H NMR (500.26 MHz, DMSO-d6, , ppm): 2.18 (3H, s, CH3), 5.66(1H, 
d ,C2 arene), 5.70(1H, d, C6 arene),5.80(1H, t, C4 arene), 6.08 (2H, m, C3, C5 arene), 7.89 
(1H, d, C4 ligand), 8.51 (1H, d, C3 ligand), 9.56 (1H, s, C6 ligand), 14.20 (1H, s, free COOH 
ligand); 13C NMR (125.79 MHz, DMSO-d6) 18.43 (CH3), 77.11 (C4 arene), 78.72 (C5 arene), 
79.32 (C3 arene), 86.53 (C6 arene), 87.99 (C2 arene), 101.46 (C1 arene), 125.29 (C3 ligand), 
130.63 (C4 ligand), 140.24 (C5 ligand), 153.28 (C6 ligand), 154.32 (C2 ligand), 164.42 (COO-
Ru), 169.56 (COOH). ESI/MS (m/z): [M‒Cl]+ = 360 and [M‒Cl‒COO+H+]+ = 317. 
 
For the characterization of the prepared complexes 1H and 13C NMR spectroscopy and 
electrospray ionization mass spectrometry (ESI-MS) were used. NMR spectra were recorded 
on a Bruker Avance III 500 spectrometer or a Bruker Ultrashield 500 Plus instrument, and 
DMSO-d6 was used as solvent. ESI-MS measurements were performed using a Micromass Q-
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TOF Premier (Waters MS Technologies) mass spectrometer equipped with electrospray ion 
source. 
 
2.3. Crystallographic structure determination  
Single crystals suitable for X-ray diffraction experiment of compounds [Ru(6-toluene)(pic)Cl] 
(1), [Ru(6-toluene)(3-Me-pic)Cl]∙H2O (2∙H2O), [Ru(6-toluene)(5-Br-pic)Cl] (3) and [Ru(6-
toluene)(2,5-dipic)Cl] (5)  were grown from methanol solution of the solid complexes.  
Orange (1) and yellow (2∙H2O, 3, 5) single crystals were mounted on loops and transferred 
to the goniometer. X-ray diffraction data were collected at ‒170 °C (for 1, 2∙H2O) or 20 °C (for 
3, 5) on a Rigaku RAXIS-RAPID II diffractometer using Mo-K radiation. A numerical 
absorption correction [33] was carried out using the program CrystalClear [34]. Sir2014 [35] 
and SHELXL [36] under WinGX [37] software were used for structure solution and refinement, 
respectively. The structures were solved by direct methods. The models were refined by full-
matrix least squares on F2. Refinement of non-hydrogen atoms was carried out with anisotropic 
temperature factors. Hydrogen atoms were placed into geometric positions (except for water 
hydrogens which were constrained). They were included in structure factor calculations but 
they were not refined. The isotropic displacement parameters of the hydrogen atoms were 
approximated from the U(eq) value of the atom they were bonded to. The summary of data 
collection and refinement parameters are collected in Table S1. Selected bond lengths and 
angles of compounds were calculated by PLATON software [38]. The graphical representation 
and the edition of CIF files were done by Mercury [39] and PublCif [40] softwares, respectively. 
The crystallographic data files for the complexes have been deposited with the Cambridge 
Crystallographic Database as CCDC x, CCDC x, CCDC x and CCDC x.  
 
2.4. pH-potentiometric measurements and data evaluation 
The pH-potentiometric measurements determining the proton dissociation and formation 
constants were carried out at 25 ± 0.1°C and an ionic strength I = 0.20 M (KCl) in order to keep 
the activity coefficient constant. The titrations were performed in a carbonate-free KOH 
solution (0.20 M). The exact concentrations of HCl and KOH were determined by pH-
potentiometric titrations. An Orion 710A pH-meter equipped with a Metrohm combined 
electrode (type 6.0234.100) and Methrom 665 Dosimat burette were used for the pH-
potentiometric measurements. The electrode system was calibrated to the pH= ‒ log[H+] scale 
by means of black titrations (strong acid HCl vs. strong base KOH), as suggested by Irving et 
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al. [41]. The average water ionization constant, pKw, was determined as 13.76 ± 0.01, which 
corresponds well to the literature data [42]. The reproducibility of the titration points included 
in the calculations was within 0.005 pH. The pH-potentiometric titrations were performed in 
the pH range 2.0 to 11.5. The initial volume of the samples was 5 mL. The ligand concentration 
was 2 mM and metal to ligand ratios of 1:1 and 1:2 were used. The accepted fitting between the 
measured and calculated titration data points regarding the volume of the titrant was < 10 µL. 
The samples were degassed by bubbling purified argon through them for 10 min prior the 
measurements and the argon was also passed over the solutions during the titrations.  
The computer program HYPERQUAD [30] was utilized to establish the stoichiometry of 
the complexes and to calculate the overall stability constants. β(MpLqHr) is defined for the 
general equilibrium: 
pM +qL+rH ⇌ MpLqHr as β(MpLqHr) ⇌ [MpLqHr]/[M]p[L]q[H]r   (1) 
where M denotes the metal moiety [Ru(η6-toluene)(Z)3] (Z = H2O/Cl‒) and L the completely 
deprotonated ligand. In all calculations exclusively titration data were used from experiments 
in which no precipitate was visible in the reaction mixture. As equilibrium constants were 
determined in the presence of 0.2 M chloride ion, they are considered as conditional constants. 
log values for the various hydroxido complexes[(Ru(6-toluene))2(2-OH)i](4-i)+ (i=2,3) were 
calculated based on the pH-potentiometric titration data in the presence of chloride ions and 
were found to be in fairly good agreement with previously published data [43].  
 
2.5. UV-vis spectrophotometric and 1H NMR spectroscopic titrations, and determination of the 
distribution coefficients 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-vis spectra 
in the interval 200 – 800 nm. The path length was 1 cm. Equilibrium constants (proton 
dissociation, stability constants and H2O/Cl
− exchange constants) and the individual spectra of 
the species were calculated with the computer program PSEQUAD [44]. The 
spectrophotometric titrations were performed in pure water on samples containing the ligands 
with or without the organometallic cation and the concentration of the ligands was 120 μM. The 
organometallic cation was also titrated (120 M) separately. The metal-to-ligand ratios were 
1:1 in the pH range from 2 to 11.5 at 25.0±0.1 °C at an ionic strength of 0.20 M (KCl). 
Measurements for 1:1 metal-to-ligand systems were also carried out by preparing individual 
samples in which KCl was partially or completely replaced by HCl; pH values, varying in the 
range ca.0.7–2.5, were calculated from the strong acid content. The absorbance data were 
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always recorded after 4 h of incubation. UV-vis spectra recorded as a function of chloride 
concentrations (0–252 mM) were used to investigate the H2O/Cl− exchange processes of 
complexes [Ru(6-toluene)(L)(H2O)] at pH 7.40 (using 20 mM phosphate buffer).  
1H NMR titrations were carried out on a Bruker Ultrashield 500 Plus instrument using 
WATERGATE water suppression pulse scheme. DSS was used as an internal NMR standard. 
1H NMR spectra of samples containing [Ru(II)(η6-toluene)(H2O)3]2+ (1 mM) and ligand picH 
(1 mM) in D2O at various pH values were recorded after 4 h of incubation (25 °C, I = 0.20 M 
(KCl)). Titration of 2 mM solution of [Ru(η6-toluene)(Z)3] was also performed separately. To 
study the interaction with HSA and N-MeIm 1H NMR spectra were recorded for samples 
containing precursor [Ru(η6-toluene)Cl(μ-Cl)]2 or complex 1 (1 mM), with or without half 
equivalent of HSA or N-MeIm. Samples were prepared in PBSʹ buffer and incubated for 24 h 
at 25 °C. 
Distribution coefficients at physiological pH (D7.4) of the complexes 1–5 and the ligands 
as well as the Ru precursor were determined by the traditional shake-flask method in n-
octanol/buffered aqueous solution at pH 7.40 at various chloride concentrations using UV-vis 
detection as described in our former work [24]. 
 
2.6. Fluorescence and membrane ultrafiltration/UV-vis studies with HSA  
Fluorescence spectra were recorded on a Hitachi-F4500 fluorometer in 1 cm quartz cell at 25.0 
± 0.1 °C. All solutions were prepared in PBS’ (pH 7.4) and were incubated for 24 h following 
a time-dependence experiment. Samples contained 1 M HSA, and various HSA-to- Ru(6-
toluene) or 1 or 2 ratios (from 1:0 to 1:10) were used. The excitation wavelength was 295 nm 
and the emission was read in the range of 310-500 nm. The quenching (KQ’) constants were 
calculated with the computer program PSEQUAD [44] using the same approach applied in our 
previous works [45,46]. 
Samples (0.50 mL) used for the ultrafiltration studies contained 40 M HSA and Ru(6-
toluene) or 1 or 2  (up to 1:10 protein-to-complex ratio) in PBS’ buffer (pH 7.4) at 25.0 ± 0.1 °C 
and were incubated for 24 h. Samples were separated by ultrafiltration through 10 kDa 
membrane filters (Millipore Amicon Ultra-0.5 centrifugal filter unit) in low (LMM) and high 
molecular mass (HMM) fractions with the help of a temperature controlled centrifuge (Sanyo, 
10000 rpm, 10 min). The LMM fraction containing the non-bound metal complex was separated 
from the protein and its adducts in the HMM fraction. The concentration of the non-bound 
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compounds in the LMM fractions was determined by UV-vis spectrophotometry by comparing 
the recorded spectra to those of reference samples without the protein.  
 
2.7. Cell lines 
Human colonic adenocarcinoma cell lines Colo 205 doxorubicin-sensitive (ATCC-CCL-222) 
and Colo 320/MDR-LRP multidrug resistant overexpressing ABCB1 (MDR1)-LRP (ATCC-
CCL-220.1) were purchased from LGC Promochem, Teddington, UK. The cells were cultured 
in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate and 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES). The cell lines were incubated at 37 °C, in a 5% CO2, 95% air atmosphere. The 
semi-adherent human colon cancer cells were detached with Trypsin-Versene (EDTA) solution 
for 5 min at 37 C.  
MRC-5 human embryonal lung fibroblast cell lines (ATCC CCL-171) wasere purchased 
from LGC Promochem, Teddington, UK. The cell line was cultured in Eagle’s Minimal 
Essential Medium (EMEM, containing 4.5 g/L glucose) supplemented with a non-essential 
amino acid mixture, a selection of vitamins and 10% heat-inactivated fetal bovine serum. The 
cell lines were incubated at 37 °C, in a 5% CO2, 95% air atmosphere.  
 
2.8. Assay for cytotoxic effect 
In the study MRC-5 non-cancerous human embryonic lung fibroblast and human colonic 
adenocarcinoma cell lines (doxorubicin-sensitive Colo 205 and multidrug resistant Colo 320 
colonic adenocarcinoma cells) were used to determine the effect of compounds on cell growth. 
The effects of increasing concentrations of compounds (complexes 1-5, the metal-free ligands, 
the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 and cis-[Pt(NH3)2(Cl)2], and the positive control   
(cisplatin (, Teva)) on cell growth were tested in 96-well flat-bottomed microtiter plates. The 
compounds were diluted in a volume of 100 μL of medium. 
The adherent human embryonal lung fibroblast cells were cultured in 96-well flat-
bottomed microtiter plates, using EMEM supplemented with 10% heat-inactivated fetal bovine 
serum. The density of the cells was adjusted to 2×104 cells in 100 μL per well, the cells were 
seeded for 24 h at 37 C, 5% CO2, then the medium was removed from the plates containing 
the cells, and the dilutions of compounds previously made in a separate plate were added to the 
cells in 200 μL. 
In case of the colonic adenocarcinoma cells, the two-fold serial dilutions of compounds 
were prepared in 100 μL of RPMI 1640, horizontally. The semi-adherent colonic 
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adenocarcinoma cells were treated with Trypsin-Versene (EDTA) solution. They were adjusted 
to a density of 2×104 cells in 100 μL of RPMI 1640 medium, and were added to each well, with 
the exception of the medium control wells. The final volume of the wells containing compounds 
and cells was 200 μL.  
The culture plates were incubated at 37 °C for 24 h; at the end of the incubation period, 
20 μL of MTT (thiazolyl blue tetrazolium bromide, Sigma-Aldrich) solution (from a stock 
solution of 5 mg/mL) were added to each well. After incubation at 37 ˚C for 4 h, 100 μL of 
sodium dodecyl sulphate (SDS) (Sigma-Aldrich) solution (10% in 0.01 M HCI) were added to 
each well and the plates were further incubated at 37 °C overnight. Cell growth was determined 
by measuring the optical density (OD) at 540/630 nm with Multiscan EX ELISA reader 
(Thermo Labsystems, Cheshire, WA, USA). Inhibition of the cell growth was determined 
according to the formula below: 
IC50  = 100100 








controlmediumODcontrolcellOD
controlmediumODsampleOD
 
Results are expressed in terms of IC50, defined as the inhibitory dose that reduces the growth of 
the cells exposed to the tested compounds by 50%.  
 
2.9. Assay for antiproliferative effect 
The method is similar to the one described in the assay described in Section 2.8 and 
antiproliferative effect of complexes 1-5, the metal-free ligands, the precursor [Ru(η6-
toluene)Cl(μ-Cl)]2 and cisplatin was determined. In the assay testing the inhibition of cell 
proliferation, 6×103 colon adenocarcinoma cells were distributed in 100 μL of medium with the 
exception of the medium control wells. The culture plates were incubated at 37 °C for 72 h and 
after the incubation time the plates were stained with MTT according to the experimental 
protocol applied for the cytotoxicity assay vide supra. 
 
3. Results and discussion 
 
3.1. Synthesis, characterization and X-ray diffraction analysis of organometallic Ru(II) 
complexes  
The Ru(II) precursor [Ru(η6-toluene)Cl(μ-Cl)]2 and the complexes of picH, 3-Me-picH, 5-Br-
picH, 2,4-dipicH2 and 2,5-dipicH2 (Chart 1) were obtained according to the literature procedure 
used for the analogous [Ru(η6-p-cymene) complexes [25-28]. Pure compounds (1-5) were 
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isolated from methanol or 2-propanol with moderate yields 50-58%. The organometallic Ru(II) 
complexes were characterized by means of standard analytical methods (1H , 13C NMR and 
ESI-MS). The 1H NMR spectra of complexes confirm the coordination of the ligands 
manifesting itself in downfield or upfield shifts of the pyridine protons (e.g. in the case of 1 the 
C3, C4 protons of the ligand are upfield while C5, C6 are downfield shifted upon coordination 
as shown in Fig. S1). Similar observations were made for the analogous Ru(II)(6-p-cymene) 
complex of picH [27]. In general, signals representing protons next to the pyridine nitrogen 
were shifted distinctly upon coordination.  
Single crystals of complexes 1, 2∙H2O, 3 and 5 were obtained by the slow diffusion 
method from methanol and their structures were determined by single crystal X-ray diffraction. 
The ORTEP representations of these complexes are depicted in Fig. 1. The complexes 1 and 
2∙H2O crystallized in monoclinic crystal systems in space group P21/n and P21, respectively.  
 
Figure 1. Molecular structures of ruthenium complexes in crystal 1 (a) in crystal 2 (b) in crystal 3 and (c) 
in crystal 5 (d). Displacement parameters are drawn at 50% probability level; hydrogen atoms and water 
molecule for 2 are omitted for clarity. 
 
The crystals 3 and 5 crystallized in triclinic crystal systems in space group P-1. All of the 
complexes adopt the so-called “piano stool” configuration, whereby toluene forms the seat and 
the chelating picolinate ligand as well as the chlorido leaving group constitute the chair legs. In 
these half-sandwich complexes the ligand is coordinated through the pyridine nitrogen and the 
carboxylate oxygen. In these structures Ru(II) is a chiral centre. In crystals 1, 3 and 5 both 
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enantiomers were crystallized in non-chiral space groups. On the other hand complex 2 
crystallized together with a solvate water molecule and only one enantiomer could be found in 
the chiral space group P21. The absolute configuration RRu could be determined according to 
CIP convention [47], the Flack parameter is 0.01(5). The molecular structures of the studied 
complexes were directly compared to that of the benzene derivative [Ru(6-C6H6)(pic)(Cl)] 
defined previously (Ref code OHUFUT [48]) which crystallized without solvate inclusion in 
triclinic P-1 space group (Fig. 2.) Selected bond distances and angles are collected in Table 1 for 
comparison. Distances between the toluene ring and the Ru ion are within the range of observed 
other ruthenium arene half-sandwich complexes (2.079(11)-2.392(7) Å) [49]. Bond lengths and 
angles do not show significant differences compared to each other (Table 1).  
 
 
Figure 2. Comparison of molecular structures of Ru(II)(η6-toluene) picolinate complexes 1 (colored by 
element), 2 (orange), 3 (yellow), 5 (violet) together with [Ru(6-C6H6)(pic)(Cl)] (CSD Ref. code 
OHUFUT) (cyan) [48]. Atoms Ru1, Cl1, N1 and O1 are superimposed. 
 
However, the angles between planes of CgA and CgB (where Cg is the centre of gravity 
calculated for rings A and B, respectively) show slight differences (Table 1 and Fig. 2). The 
methyl groups of the toluene molecule are almost in the same position for crystals 1, 2∙H2O and 
3 (the torsion angle O1-Ru1-Cg(A)-C7 is 5.5 o, 13.3o  and -7.7o degree for 1, 2∙H2O and 3, 
respectively). However, there is a significant difference in crystal 5 where the methyl group turns 
to the side of the chloride ion and this torsion angle is 116.2o). 
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Table 1. Selected bond distances (Å) and angles (o) of the studied Ru(II)(η6-toluene) picolinate 
complexes in crystals 1-3, 5 and [Ru(6-C6H6)(pic)(Cl)] (OHUFUT [48]) 
 1 2∙H2O 3 5 OHUFUT 
Bond length (Å)      
Ru1-Cl1 2.4133(5) 2.415(2) 2.405(4) 2.396(3) 2.4133(6) 
Ru1-O1 2.074(1) 2.063(6) 2.085(9) 2.093(6) 2.075(2) 
Ru1-N1 2.089(2) 2.092(8) 2.11(1) 2.095(7) 2.087(2) 
Ru1-C1 2.183(2) 2.179(9) 2.17(1) 2.21(1) 2.178(3) 
Ru1-C2 2.194(2) 2.18(1) 2.23(1) 2.17(1) 2.179(3) 
Ru1-C3 2.185(2) 2.18(1) 2.16(1) 2.14(1) 2.191(3) 
Ru1-C4 2.187(2) 2.17(1) 2.16(1) 2.16(1) 2.190(3) 
Ru1-C5 2.148(2) 2.159(8) 2.21(1) 2.14(1) 2.168(3) 
Ru1-C6 2.174(2) 2.172(9) 2.16(1)  2.16(1) 2.160(3) 
Ru1-Cg(A)a 1.6564(9) 1.656(4) 1.662(6) 1.659(5) 1.662 
Bond angles (o)      
O1-Ru1-N1 77.04(6) 76.8(3) 77.0(4) 77.4(3)  77.54(9) 
O1-Ru1-Cl1 87.44(4) 84.9(2) 85.9(3) 87.0(2) 87.04(6) 
N1-Ru1-Cl1 85.73(4) 83.7(2) 83.6(3) 84.2(2) 84.20(7) 
Cg(A)-Ru1-O1 a 127.69(5) 129.3(2) 129.6(4) 128.4(3) 128.77 
Cg(A)-Ru1-N1 a 132.73(5) 133.6(2) 134.2(4) 132.8(3) 132.55 
Cg(A)-Ru1-Cl1 a 128.74(4) 129.66(17) 128.2(2) 129.1(2) 128.97 
Cg(A)-Cg(B)b 52.94(9) 64.1(5) 61.9(7) 58.9(6) 55.30 
O1-Ru1-Cg(A)-Cl1 5.5 13.3 -7.8 116.2 - 
a Cg is the centre of gravity calculated for ring A. b Angles between planes calculated for  
rings A and B. 
 
The positions of the picolinate ligands are slightly different in the studied complexes due 
to secondary interactions with adjacent molecules as different molecular arrangements and 
solvate inclusion (for crystal 2∙H2O) realized in these crystal structures. The packing 
arrangements are shown in Figs. S2-S4 viewing along selected crystallographic axes. The main 
secondary interactions between molecules are C-H…O hydrogen bonds between the toluene 
hydrogens and the carboxylate oxygen (O1) of the picolinate ligand. Beside the hydrogen bonds 
considerable secondary interactions are formed between neighboring complexes by C-H…Cl 
interactions (e.g. C12-H12…Cl1 in 2∙H2O and C5-H5…Cl1 in 4, Table S2 and Figs. S3 and S5). 
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3.2. Proton dissociation processes of the studied ligands and hydrolysis of [Ru(6-
toluene)(H2O)3]
2+ organometallic cation 
Proton dissociation constants of the ligands picH, 3-Me-picH, 5-Br-picH, 2,4-dipicH2 and 
2,5-dipicH2 (Chart 1) were determined by pH-potentiometric and UV-vis spectrophotometric 
titrations performed in the pH range from 2 up to 11.5 (Table 2). Molar absorbance spectra of 
the ligand species in the different protonation states were calculated via the deconvolution of 
the spectra recorded at various pH values as it is shown in Fig. S6 for 5-Br-picH. The pKa value 
picH and the calculated molar absorbance spectra of the HL and L‒ forms are in reasonably 
good agreement with data reported previously [23,50]. The protonated compounds picH, 3-Me-
picH, 5-Br-picH possess two, while 2,4-dipicH2 and 2,5-dipicH2 have three dissociable protons. 
It was found in all cases that the first deprotonation step assigned to the carboxylic group at 
position 2 takes place in a fairly acidic range and no pKa values could be determined for this 
process. Therefore this carboxylate remains deprotonated in the whole studied pH range. pKa 
determined for picH, 3-Me-picH, 5-Br-picH can be attributed to the deprotonation of the 
pyridinium (NH+) group as well as the higher pKa of 2,4-dipicH2 and 2,5-dipicH2. The lower 
pKa of the latter two ligands belongs to the carboxylic group at position 4 and 5, respectively. 
Comparing the pKa values to that of Hpic, it is worth mentioning that the methyl substituent has 
no measurable effect at position 3, while the bromo and the carboxylic groups decrease the 
pKa (NH
+) significantly due to the electron withdrawing power of the halogen substituent and 
the mesomeric effect of the COO‒ moiety. 
Based on the determined pKa values it can be declared that all the studied ligands are 
present in their completely deprotonated forms (L‒: pic, 3-Me-pic, 5-Br-pic; L2‒: 2,4-dipic, 2,5-
dipic) at pH 7.4 resulting in their strongly hydrophilic character (logD7.4 < ‒2).    
 
Table 2. Proton dissociation constants (pKa) of the studied ligands determined by pH-potentiometric 
and UV-vis spectrophotometric titrations; max and molar absorptivity () values for the ligand species 
in the different protonation states. {T = 25.0˚C, I = 0.20 M (KCl)} 
 Method pKa 
(COOH) 
pKa (NH+)  max (nm) /  (M-1cm-1) 
pic pH-metry 
UV-vis 
< 1 
< 1 
5.13 ±0.03 
5.07 ±0.01 
 HL: 263 / 7100 
L‒: 263 / 3900 
3-Me-pic pH-metry 
UV-vis 
< 1 
< 1 
5.16 ±0.03 
5.16 ±0.03 
 HL: 274 / 6820 
L‒: 268 / 4400 
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5-Br-pic pH-metry 
UV-vis 
< 1 
< 1 
3.44 ±0.02 
3.34 ±0.04 
 HL: 278 / 6570; 240 / 9770 
L‒: 268 / 4400; 232 / 10650 
2,4-dipic pH-metry 
UV-vis 
1.84 ±0.05 
1.9 ±0.1 
4.70 ±0.02 
4.56 ±0.08 
 H2L: 278 / 5100 
HL‒: 274 / 5980 
L2‒: 276 / 3700 
2,5-dipic pH-metry 
UV-vis 
2.19 ±0.05 
2.16 ±0.02 
4.63 ±0.04 
4.57 ±0.01 
 H2L: 272 / 6900 
HL‒: 272 / 7100 
L2‒: 272 / 5500 
 
Hydrolytic behavior of the organometallic cation [Ru(6-toluene)(H2O)3]2+ has been 
already studied by Buglyó et al. in the presence and in the absence of chloride ions [43]. In the 
latter case the fast hydrolysis of the aquated organoruthenium cation yields the species [(Ru(6-
toluene))2(μ2-OH)3]+ that becomes predominant at pH > 5. When 0.2 M KCl was used as the 
background electrolyte, as in our studies, formation of various chlorido and mixed 
chlorido/hydroxido species as intermediates was found in addition to the major hydrolysis 
product [(Ru(6-toluene))2(μ2-OH)3]+. In a good accordance with their findings based on the 
combined use of 1H NMR spectroscopy and ESI-MS, we have also detected three different 
species based on the 1H NMR spectra recorded at various pH values (Fig. S7). Namely, the 
identified species are [Ru(6-toluene)(H2O)2Cl]+ (= M), [(Ru(6-toluene))2(-OH)2Cl]+ (= 
[M2(OH)2]) and [(Ru(6-toluene))2(-OH)3]+ (= [M2(OH)3]+). Overall stability constants for 
the dinuclear hydrolysis products [(Ru(6-toluene))2(2-OH)i](4-i)+ (i=2,3) were determined by 
pH-potentiometric and UV-vis spectrophotometric titrations at 0.2 M chloride ion concentration 
(Table 3) and are in good agreement with data obtained by Buglyó et al. using pH-potentiometry 
[43]. Notably these are conditional stability constants being valid only at 0.2 M KCl ionic 
strength. Concentration distribution curves were computed on the basis of the stability constants 
determined by pH-potentiometry showing that the hydrolysis is suppressed somewhat due to 
the presence of chloride ions, since [M2(OH)3] dominates only at pH > 6 (Fig. S8). The 
1H 
NMR signals of the three kinds of species (M, [M2(OH)2], [M2(OH)3]) could be integrated and 
distribution of the organometallic fragment was calculated showing an acceptable match 
between the two kinds of methods. 
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3.3. Complex formation equilibria of [Ru(6-toluene)(H2O)3]2+ with the picolinate ligands: 
stability, deprotonation, chloride ion affinity and lipophilicity 
Complexation processes were studied by the combined use of pH-potentiometric, UV-vis 
spectrophotometric titrations and 1H NMR spectroscopy in a 0.2 M chloride-containing 
medium. Therefore the formation (logK [ML]) and deprotonation (pKa [ML]) constants 
determined herein are considered as conditional stability constants. The complex formation 
between [Ru(6-toluene)(H2O)3]2+ and the studied bidentate picolinate ligands follows a fairly 
simple scheme (Chart S1). Namely a mono complex [Ru(6-toluene)(L)(Z)] (=[ML]) is formed, 
and a mixed hydroxido species [ML(OH)] appears by the deprotonation of the coordinated H2O 
molecule and/or by the displacement of the chlorido co-ligand by OH‒ in the basic pH range, 
similarly to the behavior of analogous half-sandwich Ru(6-p-cymene) complexes [22,23]. The 
complex formation of the organometallic cation with the picolinate ligands was found to be a 
rather slow process. E.g. the steady state could be reached after more than 35 min in the [Ru(6-
toluene)(H2O)3]
2+ ‒ picH system at pH 2.8 as the time-dependence of the UV-vis spectra 
indicates (Fig. 3). This slow reaction hindered the application of conventional pH-
potentiometric titrations to determine the logK [ML] values. In order to solve this problem, 
individual samples were prepared by the addition of different amount of strong base under 
argon, and the UV-vis spectra and the actual pH values were measured after 4 h. Based on the 
recorded spectra it could be concluded that the complex formation proceeds in a great extent 
already at pH 2 in all cases. As a consequence logK [ML] constants were determined from the 
UV-vis spectral changes of the metal-to-ligand charge-transfer (Ru 4d6→π*) and ligand (π 
→π*) transition bands in the pH range from 0.7 to 3.0 in the case of 3-Me-pic and 2,4-dipic 
(Table 2). On the other hand, the spectra were unchanged from pH 3 down to pH 0.7 in the 
[Ru(6-toluene)(H2O)3]2+ – pic/5-Br-pic/2,5-dipic systems showing negligible decomposition 
of the complexes under such strongly acidic conditions. Thus for the logK [ML] constants only 
a lower limit could be estimated (Table 3). Based on these findings the complexation of pic 
with [Ru(6-p-cymene)(H2O)3]2+ was reinvestigated using longer incubation times (4 h) needed 
to reach steady state in the presence of chloride ions (0.2 M KCl) and a higher logK [ML] value 
(>11.5) was obtained than previously published [23].  
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Figure 3. Time-dependence of UV-vis absorption spectra recorded for the [Ru(6-toluene)(H2O)3]2+ ‒ 
picH (1:1) system in the presence of chloride ions. The inset shows the absorbance changes at 310 nm. 
{cRu = 102 M; T = 25 ˚C; I = 0.20 M (KCl); ℓ = 1.0 cm}. 
 
Table 3. Stability constants logK [ML], pKa [ML] values of the [Ru(6-toluene)(H2O)3]2+ complexes 
formed with picolinate ligands in 0.2 M chloride-containing aqueous solutions determined by various 
methods; H2O/Cl− exchange constants (logK’) for the [Ru(6-toluene)(L)(H2O)]+ complexes and pM* 
values at pH = 7.4 (pM* = −log([M] + [M2(OH)3] + [M2(OH)2]) at cM = 100 μM). {T = 25.0 ˚C, I = 
0.20 M (KCl)} 
  logK [ML] pKa [ML] pKa [ML] pM* logK’ 
(H2O/Cl−) 
ligand complex UV-vis UV-vis pH-metry  UV-vis 
pic 1 >10.6 a 8.53 ±0.01 b 8.47 ±0.01 b >5.8 1.33 ±0.01 
3-Me-pic 2 9.87 ±0.01 8.71 ±0.01 8.68 ±0.05 5.3 1.32 ±0.01 
5-Br-pic 3 > 8.9 a 8.47 ±0.01 8.41 ±0.03 >4.7 1.50 ±0.01 
2,4-dipic 4 11.22 ±0.07 8.44 ±0.01 8.37 ±0.06 6.2 1.23 ±0.01 
2,5-dipic 5 > 11.9 a 8.58 ±0.01 8.38 ±0.07 >6.7 1.09 ±0.01 
a Estimated values based on UV-vis spectrum recorded at pH 0.7; b pKa [ML] values based on 1H NMR 
titrations: 8.52 ±0.09 (0.2 M KCl) and 7.87 ±0.09 (0 M KCl) 
 
Increasing the pH values the studied [ML] complexes may undergo a combination of 
deprotonation and decomposition. Deprotonation of the coordinated water molecule (and/or Cl‒
→OH‒ exchange) results in the formation of mixed hydroxido [ML(OH)] complexes, while 
decomposition can yield unbound ligand and metal ion in hydrolyzed forms depending on the 
actual pH. The recorded UV-vis spectra were the same in a wide pH range (e.g. in the [Ru(6-
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toluene)(H2O)3]
2+ ‒ 3-Me-picH system at pH between 3.1 and 7.6 shown in Fig. 4) , while 
significant spectral changes are observed at pH > 8 due to the formation of [ML(OH)]. The 
appearance of isosbestic points suggests that the metal complexes do not decompose under 
these conditions; merely they are deprotonated almost in all cases. It should be noted that the 
complex of 5-Br-pic showed a low extent of decomposition in the basic pH-range. Based on 
these spectral changes pKa [ML] constants were determined for the complexes (Table 3). 
Notably, the spectra of the complexes did not change over a 24 h period at both pH 7.4 and 11 
values, and the deprotonation process was found to be rather fast. Therefore pH-potentiometric 
titrations were also performed to determine pKa [ML] constants (Table 3) started from pH ~4 
but only after a 4 h waiting period whilst the formation of [ML] becomes complete. pKa [ML] 
constants obtained by the two kinds of methods are in a good agreement.   
 
 
Figure 4. UV-vis absorption spectra recorded for the [Ru(6-toluene)(H2O)3]2+ ‒ 3-Me-picH (1:1) 
system in the presence of chloride ions in the pH range from 3 up to 11. The inset shows the absorbance 
changes at 306 nm at pH between 0.7 and 11. {cRu = 102 M; T = 25 ˚ C; I = 0.20 M (KCl); ℓ = 1.0 cm}. 
 
In addition 1H NMR spectra were also recorded for the [Ru(6-toluene)(H2O)3]2+ – pic 
system in the presence of 0.2 M chloride ions at a 1:1 metal-to-ligand ratio at various pH values 
using 4 h incubation time (Fig. 5). The spectra undoubtedly reveal that neither a free metal ion 
nor a ligand is present in the whole pH range studied (pH = 2 – 11.5), which means that the 
complex does not suffer from decomposition at 1 mM concentration due to its high stability. 
The aqua [ML(H2O)] and the chlorinated [ML(Cl)] complexes were identified in the acidic pH 
range. An upfield shift of all peaks belonging to the [ML(H2O)] complex is observed in the 
basic pH range due to the fast exchange process on the NMR time scale between the aquated 
and the mixed hydroxido [ML(OH)] species. In the meanwhile the intensity of the peaks 
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belonging to the [ML(Cl)] complex is decreased. Based on the integrals of the CH(6) toluene 
proton in the acidic pH range the [ML] complex is mainly chlorinated (~83% [ML(Cl)]). As 
the [ML(OH)] starts to be formed the three species are present together in the solution, and their 
equilibrium concentrations cannot be simply calculated due to the fast exchange process. 
Figure 5. 1H NMR spectra of [Ru(6-toluene)(H2O)3]2+ ‒ picH (1:1) system in aqueous solution in the 
presence of 0.2 M chloride ions at the indicated pH values in the regions of the ligand protons (a), the 
toluene CH protons (b) and the toluene CH3 protons (c). {cRu = 1 mM; T = 25 ˚C; I = 0.20 M (KCl); 
D2O; pH = pD×0.93+0.40 [51]}. 
 
Therefore, the pKa of the aqua [ML(H2O)] was determined (pKa = 7.87 ±0.09) based on the pH-
dependent chemical shift (δ) values of [ML(H2O)] and [ML(OH)] species. (Notably this value 
equals to the pKa [ML] in the chloride-free medium.) Using this constant the ratio of the latter 
two species can be calculated at any chosen pH and then the actual concentrations of all the 
three complexes could be computed (Fig. 6). From the ratio of the summed concentration of 
[ML(Cl)] and [ML(H2O)]  (as [ML] species) and that of [ML(OH)] pKa [ML] in the 0.2 M 
chloride-containing medium was calculated (Table 3) representing a good match to the data 
obtained by the other two methods. 
[MLCl]
[ML(OH)]
9.5    9.0   8.5    8.0   7.5              6.0       5.5          2.38     2.15  
 / ppm
(a) (b) (c) pH =
11.40
10.43
9.56
8.96
8.60
8.02
7.56
6.96
6.14
3.59
2.54[
M
L
(H
2
O
)]
+
22 
 
 
Figure 6.  Distribution of Ru(6-toluene) in the [Ru(6-toluene)(H2O)3]2+ ‒ picH (1:1) system in the 
presence of 0.2 M chloride ions in the pH range from 2 up to 10 based on the 1H NMR peak integrals 
for the CH(6) toluene proton of species identified based on Fig. 5. The ratio of the [ML(H2O]+ and 
[ML(OH)] at a given pH is calculated using the pKa [ML] of the aqua complex. {cRu = 1 mM; T = 25 ˚C; 
I = 0.20 M (KCl)}. 
 
In order to compare the stability of the studied Ru(6-toluene) complexes of the different 
picolinates to each other pM* values were computed using the experimentally determined 
equilibrium constants (Table 3). pM is the negative logarithm of the equilibrium concentration 
of the unbound metal ion, and a higher pM value indicates a stronger metal ion binding ability 
of the ligand under given circumstances. Due to the hydrolysis of the Ru(6-toluene) fragment 
pM* was computed reflecting the unbound fraction of the metal ion where pM* = −log([M] + 
[M2(OH)2] + [M2(OH)3]). These pM* values indicate the formation of relatively high stability 
complexes suggesting the following stability order at pH 7.4: 5 > 4 > 1 > 2 > 3. E.g. 
decomposition of 1% and 20% are estimated for complexes 1 and 3 at 100 μM concentration, 
respectively. Based on the speciation data it can be concluded that the complexes are present 
mainly in their [ML] forms at pH 7.4, and they are only partly deprotonated ([ML(OH)] ~ 10%) 
in the 0.2 M chloride-containing medium. 
The ratio of the chlorinated and aqua complexes ([ML(Cl)] and [ML(H2O)]) can be 
characterized by the H2O/Cl
‒ exchange constant, which was determined by UV-vis 
spectrophotometry using the same approach that we used in our previous works for analogous 
Rh(5-C5Me5) complexes [52,53]. Representative UV-vis spectra recorded at various chloride 
ion concentrations for the complex 1 and the measured and fitted absorbance values are shown 
in Fig. S9. Notably a lower H2O/Cl
‒ exchange constant allows an easier replacement of Cl‒ by 
water or by donor atoms of biomolecules. The logK’ (H2O/Cl−) values (Table 3) obtained for 
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1-5 reflect a moderate affinity towards chloride ions which is much lower compared to e.g. the 
analogous Rh(5-C5Me5) picolinate complexes [52,53]. The dependence of cytotoxicity on 
chloride ion affinity has been reported for several Ru(η6-arene) complexes [54], however many 
other factors such as lipophilicity have a strong influence on the pharmacological activity. 
Therefore, distribution coefficients at pH 7.4 (logD7.4) were determined for the complexes 1-5, 
for the metal-free ligands and for the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 at various chloride 
ion concentrations according to the chloride content of blood serum: ~100 mM, cell plasma: 
~24 mM and cell nucleus: ~4 mM. The precursor, the ligands, the complexes 2, 4 and 5 were 
found to be very hydrophilic at each studied chloride ion concentration (logD7.4 < ‒2.5). logD7.4 
values only for complexes 2 and 3 could be determined accurately by the applied n-octanol-
water partitioning (Fig. 7), and they exhibit increasing lipophilicity with increasing chloride ion 
concentration, although even at 100 mM they are considered as fairly hydrophilic compounds. 
They have stronger hydrophilic character in the presence of less chloride ions since they are 
more aquated and the  complex turns to be charged ([ML(Cl)] → [ML(H2O]+). 
 
Figure 7. n-Octanol/water distribution coefficients at pH 7.4 (logD7.4) for complexes 2 (white bars) and 
3 (grey bars) at various chloride ion concentrations {T = 25 °C, pH = 7.4 (20 mM phosphate buffer)} 
 
3.4. Cytotoxic and antiproliferative activity in human cancer cell lines 
In order to evaluate the biological effects of complexes 1-5, antiproliferative and cytotoxicity 
assays were applied in doxorubicin-sensitive (Colo 205) and multidrug resistant (Colo 320) 
human colonic adenocarcinoma cell lines. The resistance of Colo 320 cells is primarily 
mediated by the overexpression of ABCB1 (P-glycoprotein), a member of the ATP-binding 
cassette (ABC) transporter family, which pumps out xenobiotics from the cells. Cytotoxicity 
was measured in normal human embryonal lung fibroblast cells (MRC-5) as well. In addition 
the corresponding free ligands and the precursor [Ru(η6-toluene)Cl(μ-Cl)]2 were tested for 
-2.5 -2 -1.5 -1 -0.5 0
logD7.4 of complexes 
4 mM
24 mM
100 mM
c (Cl-):
-1.4  0.2
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-1.16  0.01
-1.60  0.07
-2.4  0.2
24 
 
comparison. In case of the antiproliferative assay, a low cell number (6×103 cells/well) was 
chosen and the incubation period of the MTT assay was longer (72 h). Using these conditions 
information can be provided about the activity of the complexes to inhibit cell proliferation. In 
case of the cytotoxicity assay, a high cell number (2×104 cells/well) was used and the inhibition 
of cell growth was determined after 24 h by MTT assay. The latter assay is an important tool to 
investigate the toxicity of the complexes. In both assays cisplatin was used as a positive control. 
IC50 values are collected in Table S3. The ligands and the precursor did not show either 
cytotoxic or antiproliferative activities (IC50 >100 μM).  
The complexes 1-5 did not possess any cytotoxic activity on the colon adenocarcinoma 
cell lines and on the normal MRC-5 human embryonic fibroblast cells. On the other hand the 
complexes 1 and 2 showed a moderate antiproliferative effect on the MDR Colo 320 colon 
adenocarcinoma cell line with IC50 values of 84.84 ± 4.79 and 79.19 ± 6.71 μM, respectively. 
Interestingly, these complexes had greater activity on the MDR cell line than on the sensitive 
Colo 205 cell line implying the selectivity of these complexes towards the MDR colon 
adenocarcinoma cell line. 
 
Table 4. pKa of the complexes [ML(H2O)]+ in the absence and in the presence of chloride ions at 0.2 M 
ionic strength, the Cl‒/H2O exchange constants (logK’ (H2O/Cl‒) for the [ML(H2O)]+ + Cl‒ ⇌ [ML(Cl)] 
+ H2O equilibrium, estimated ratio of the chlorinated complex [ML(Cl)] at 4 and 100 mM  chloride ion 
concentrations, and representative IC50 values measured in human cancer cells for the complexes of 
[Ru(6-toluene)(pic)Cl], [Ru(6-p-cymene)(pic)Cl], [Os(6-p-cymene)(pic)Cl] and [Rh(5-
C5Me5)(pic)Cl]. 
 1 [Ru(6-p-
cymene)(pic)Cl] 
[Os(6-p-
cymene)(pic)Cl] 
[Rh(5-
C5Me5)(pic)Cl] 
pKa (0 M Cl‒) 7.87 8.00 b 6.67 d 9.32 e 
pKa (0.2 M Cl‒) 8.53 8.90 b n.d. 10.44 e 
logK’ (H2O/Cl‒) 1.33 1.83 b n.d. 2.20 e 
rate of Cl‒/H2O 
 
[ML(Cl)] fraction 
 c(Cl‒) = 4 mM 
fast 
 
 
68% 
fast b 
 
 
87% b 
slower d 
t1/2 ~ 12 min 
 
100% d 
fast e 
 
 
94% e 
c(Cl‒) = 100 mM 8% 22% b 28% d 36% e 
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IC50 (M) 84.84±4.79  
(Colo320) 
a 
82 (HeLa) c 
36 (FemX) c 
17 (A549) d 
4.5 (A2780) d 
343 (A549) e 
258 (CH1) e 
a Antiproliferative activity; b Data taken from Ref. 23.; c Data taken from Ref. 27.; d Data taken from Ref. 29.; e 
Data taken from Ref. 52. 
 
Among the half-sandwich organometallic complexes of picolinic acid reported in the 
literature [Os(6-p-cymene)(pic)Cl] has the highest cytotoxic effect [29], [Ru(6-p-
cymene)(pic)Cl] is moderately cytotoxic [27], while compounds [Ru(6-toluene)(pic)Cl] (1) 
and [Rh(5-C5Me5)(pic)Cl] [52] possess much lower activity. In order to compare these 
complexes for getting insight their different biological activity some physico-chemical 
properties such as pKa [ML], logK’ (H2O/Cl‒) are collected in Table 4. A low pKa [ML] is 
generally considered to be unfavorable as the chance for the formation of the ternary mixed 
hydroxido [ML(OH)], that is believed to be less prone to interact with biomolecules [55], 
becomes higher at pH 7.4. In this context the Os(II) complex would be expected to be the least 
active. The effect of a strong chloride ion affinity (higher logK’ (H2O/Cl‒), thus higher fraction 
of the chlorinated complex) can be dual. If the affinity is high the complex can retain the original 
chlorido ligand coordinated more efficiently in the serum and the neutral [ML(Cl)] complex 
can go across the cell membrane easier via passive transport. Additionally the lipophilicity of 
the complex should be also optimal; however no logD7.4 values are available for most of these 
complexes. On the other hand, after entering the cell, it is assumed that the lower intracellular 
chloride content can induce partial aquation of the complexes leading to the formation of the 
active aqua complex. When the chloride affinity is high, the replacement of Cl‒ by water or 
donor atoms of proteins is aggravated. Besides these properties the reaction rate of the 
displacement reaction is also an important factor. Based on these parameters it seems that 
relatively slow kinetics of the Os(II) complex is advantageous. Whilst the strong hydrophilic 
character, fast Cl‒/water exchange process of the [Ru(6-toluene)(picolinate)Cl] studied in this 
work can be at least partly responsible due to the lack of their cytotoxicity.         
   
3.5. Interaction of complexes 1 and 2 with human serum albumin 
HSA is the most abundant plasma protein and serves as a transport vehicle for a wide variety 
of endogenous compounds and pharmaceuticals. Binding to HSA has a strong impact on the 
pharmacokinetic properties of drugs. In addition HSA-bound drugs are known to accumulate 
in solid tumors as a consequence of the enhanced permeability and retention effect, which can 
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be an operative way of selective tumor targeting [56]. This protein has various metal binding 
sites such as the N-terminal site, the reduced Cys34 residue, the multi-metal binding site and 
certain side chain donor atoms such as imidazole nitrogens of His are also able to coordinate to 
the metal ions [57,58]. On the other hand nonspecific binding pockets located in subdomains 
IIA and IIIA are willing to accommodate compounds of a wide variety [58]. In all diversified 
binding modes are possible for potential metallodrugs. 
Interaction of complexes 1 and 2 representing moderate antiproliferative activity (see 
Section 3.4) towards HSA was studied by mainly ultrafiltration/UV-vis and spectrofluorometric 
methods. All measurements were performed at pH 7.4 at 25 ºC using a modified phosphate 
buffered saline (PBS’) in which the concentration of the chloride ions corresponds to that of the 
human blood serum. First of all binding of 1 to HSA was monitored by 1H NMR spectroscopy. 
Spectra were recorded for 1 in the absence or in the presence of the protein after a 24 h 
incubation period (Fig. S10). (This incubation time was chosen as the preliminary time-
dependence studies showed that the reaction is relatively slow, depending on the conditions 
several hours are needed to reach the equilibrium state.) It was found that the signal of the 
toluene methyl group is shifted in the presence of HSA and no free ligand was detected. These 
observations strongly suggest the formation of ternary adducts with the protein without ligand 
cleavage. Then the direct interaction of complexes 1, 2 and the [Ru(η6-toluene)Cl(μ-Cl)]2 
precursor was followed by ultrafiltration. The unbound, low molecular mass (LMM) fractions 
after separation were analyzed by UV-vis quantification. Analysis of the recorded spectra 
confirmed that the complexes 1, 2 are intact upon binding as we could not detect free ligand in 
the LMM fraction (Fig. S11). Comparing the spectra recorded after the separation to reference 
spectra the ratio of the bound compounds per HSA was calculated and plotted against the ratio 
of the total concentrations of the complexes and the protein (Fig. 8).       
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Figure 8. Ratio of the bound complexes (Ru precursor, 1 and 2) and HSA plotted against the ratio of 
the total concentrations of the complexes and HSA calculated from the UV-vis spectra recorded for the 
LMM fractions of the ultrafiltered samples. {Original sample composition: HSA: 40 µM; complexes: 0-
400 µM; T = 25 ˚C; pH = 7.4 in PBS’; incubation time: 24 h}. 
 
These formation curves show the binding at multiple sites for the Ru precursor and for the 
complexes, although no saturation could be achieved up to the applied 10-fold complex excess. 
The binding of the precursor is almost quantitative, but realized at a lower level compared to 
the Rh(5-C5Me5) precursor [45]. The binding of 1 is somewhat weaker compared to 2; 
however at least 3 or 5 binding sites are feasible for them, respectively.    
 
 
Figure 9. Changes of fluorescence emission intensities at 338 nm plotted against the complex-to-HSA 
ratios for 1 (●), 2 (×) and the Ru precursor (▲) using 295 nm excitation and 340 nm emission 
wavelengths. {cHSA = 1 µM; complexes: 0-10 µM; T = 25 ˚C; pH = 7.4 in PBS’; incubation time: 24 h}. 
 
 In order to obtain preliminary information about the binding sites the interaction of 1, 2 
and the Ru(II) precursor were monitored by fluorometry. HSA contains a single Trp (214) 
residue near site I (at subdomains IIA) that is responsible for the majority of the intrinsic 
fluorescence of the protein. Upon excitation at 295 nm its emission can be attenuated by a 
binding event close to Trp214 [58,59]. It is worth mentioning that coordination of protein side 
chains such as histidine nitrogens (e.g. His242) [59] located nearby this site to the ruthenium 
complexes by the substitution of the chlorido/aqua ligand at the third coordination site is very 
feasible. Addition of the Ru(II) compounds to HSA quenches the Trp214 fluorescence emission 
(Fig. 9) indicating that the conformation of the hydrophobic binding pocket is significantly 
affected upon their binding. Based on the emission intensity changes quenching constants were 
computed. LogKQʹ values of 5.25 ±0.01, 4.16 ±0.01 and 4.18 ±0.01 were obtained for the Ru 
precursor, 1 and 2, respectively. These values reflect fairly strong binding of the precursor, and 
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a moderate and similar binding of 1 and 2 at this particular site of HSA. As more than one 
binding sites are suggested on the basis of the ultrafiltration measurements, the complexes 1 
and 2 (as well as the precursor) should be bound on other sites beside site I as well, such as the 
more accessible surface donors. Among the side chain donors His, Met and Cys residues are 
suggested to be responsible to coordinate to Ru complexes [60,61]. The prominent role of His 
was pointed out in the case of Rh(5-C5Me5) complexes in our former work [45]. Therefore 
interaction of 1 and the precursor with 1-methylimidazole (N-MeIm), a monodentate model 
compound of His, was screened by 1H NMR spectroscopy. It was found that 95% the Ru(II) 
precursor is bound to N-MeIm at 1:1 ratio (Fig. S12), while 100% of the analogous [Rh(5-
C5Me5)Cl(μ-Cl)]2 precursor is bound under the same condition [45]. In the case of complex 1 
the original picolinate ligand was not replaced by the model compound but formation of ternary 
[Ru(η6-toluene)(pic)(N-MeIm)] complex of significant fraction (1: 85%) was observed (Fig. 
S13). This observation confirms the feasible coordination of the imidazole nitrogen of His at 
the third coordination site of the studied picolinate complexes.    
 
4. Conclusions  
Metal complexes of 2-picolinic acid and its 3-methyl, 5-bromo, 4-carboxylic, 5-carboxylic 
derivatives formed with Ru(6-toluene) organometallic fragment were synthesized and 
characterized in solid phase and in solution. The structures of four complexes were also 
determined by single-crystal X-ray diffraction showing a pseudo-octahedral “pianostool” 
geometry, and the deprotonated picolinates bind in a bidentate mode via (N,O) donor atoms and 
the coordination sphere is completed by a chlorido ligand. Complex formation equilibrium 
processes were studied in aqueous solution by the combined use of UV-visible 
spectrophotometry, pH-potentiometry and 1H NMR spectroscopy in the presence of chloride 
ions in addition to the characterization of the proton dissociation equilibria of the ligands. The 
complex formation reached a significant extent already at pH 0.7 representing prominently high 
stability and was found to be relatively slow (ca. 35 min); while deprotonation of the complex 
and water/chloride exchange processes took place fast. By means of these methods we could 
demonstrate exclusive formation of mono complexes such as [Ru(6-toluene)(L)(Z)] (L: 
completely deprotonated ligand; Z = H2O/Cl
‒) and [Ru(6-toluene)(L)(OH)] in solution. 
Moderate pKa values (8.3-8.7) were obtained reflecting the formation of ca. 10% mixed 
hydroxido species at pH 7.4 in the presence of 0.2 M KCl. The chloride ion affinity of the 
complexes was characterized by moderate H2O/Cl
− co-ligand exchange equilibrium constants 
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(logK’ H2O/Cl− = 1.1-1.5) which are lower than those of the analogous Ru(6-p-cymene) and 
Rh(5-C5Me5) compounds.  
All the studied metal complexes exhibit a rather hydrophilic character at 100 mM 
chloride concentration and become even more hydrophilic at lower chloride content. The 
studied complexes were not cytotoxic against colon adenocarcinoma cell lines and normal 
MRC-5 human embryonic fibroblast cells. However, the complexes formed with 2-picolinic 
acid (1) and its 3-methyl derivative (2) represented a moderate antiproliferative effect (IC50 = 
84.84, 79.19 μM) on the multidrug resistant Colo 320 colon adenocarcinoma cell line revealing 
considerable MDR selectivity. Interaction of complexes 1 and 2 with the blood transport protein 
HSA was investigated by ultrafiltration and fluorometry. The binding is relatively slow and no 
ligand cleavage was observed, thus formation of ternary adducts with the protein via 
coordination bonds at several binding sites (at least 3-5) is suggested. Complex 1 represents a 
somewhat weaker overall binding compared to 2, while their binding at site I is fairly similar 
based on the Trp(214) quenching studies. 1-methylimidazole binds efficiently to these 
complexes at the third coordination site suggesting the probable binding of imidazole nitrogens 
of the protein with non-dissociative characteristics.        
 
Abbreviations: 
5-Br-picH 5-bromo-2-pyridinecarboxylic acid 
cisplatin  cis-[Pt(NH3)2(Cl)2] 
D7.4 distribution coefficients at physiological pH 
2,4-dipicH2 2,4-pyridinedicarboxylic acid  
2,5-dipicH2 2,5-pyridinedicarboxylic acid 
DSS  4,4-dimethyl-4-silapentane-1-sulfonic acid 
EMEM  Eagle’s Minimal Essential Medium 
HSA human serum albumin 
MDR multidrug resistance  
3-Me-picH 3-methylpyridine-2-carboxylic acid 
MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
NKP-1339 sodium trans-[Ru(III)Cl4(Ind)2], Ind = indazole; IT-139 
N-MeIm 1-methylimidazole 
PBS’ modified phosphate-buffered saline 
picH  pyridine-2-carboxylic acid, 2-picolinic acid 
UV-vis UV-visible  
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